EBS vs. NVO
EBS (Emergent BioSolutions Inc.) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — EBS in Drug Manufacturers - Specialty & Generic, NVO in Drug Manufacturers - General. Over the past 10 years, EBS returned -11.85%/yr vs 8.27%/yr for NVO. At a 0.23 correlation, their price movements are largely independent.
Performance
EBS vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, EBS achieves a -36.49% return, which is significantly lower than NVO's -6.67% return. Over the past 10 years, EBS has underperformed NVO with an annualized return of -11.85%, while NVO has yielded a comparatively higher 8.27% annualized return.
EBS
- 1D
- -1.88%
- 1M
- -7.10%
- YTD
- -36.49%
- 6M
- -38.72%
- 1Y
- 26.21%
- 3Y*
- -5.56%
- 5Y*
- -33.43%
- 10Y*
- -11.85%
NVO
- 1D
- 6.23%
- 1M
- 2.05%
- YTD
- -6.67%
- 6M
- -1.28%
- 1Y
- -34.91%
- 3Y*
- -14.58%
- 5Y*
- 4.55%
- 10Y*
- 8.27%
EBS vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
EBS Emergent BioSolutions Inc. | -36.49% | 29.29% | 298.33% | -79.68% | -72.83% | -51.48% | 66.08% | -8.99% | 27.57% | 41.50% |
NVO Novo Nordisk A/S | -6.67% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
Correlation
The correlation between EBS and NVO is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.16 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Nov 15, 2006 | 0.23 |
The correlation between EBS and NVO shifts across timeframes, from 0.14 (3 years) to 0.27 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
EBS:
-$0.37
NVO:
DKK 27.42
EBS:
0.49
NVO:
4.06
EBS:
$676.80M
NVO:
DKK 327.80B
EBS:
$292.40M
NVO:
DKK 268.30B
EBS:
$126.60M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
EBS vs. NVO — Risk / Return Rank
EBS
NVO
EBS vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Emergent BioSolutions Inc. (EBS) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| EBS | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.99 | ||
| Sortino ratioReturn per unit of downside risk | +1.86 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 0.90 | +0.26 |
| Calmar ratioReturn relative to maximum drawdown | 0.59 | -0.71 | +1.31 |
| Martin ratioReturn relative to average drawdown | 1.06 | -1.13 | +2.19 |
Loading charts...
Drawdowns
EBS vs. NVO - Drawdown Comparison
The maximum EBS drawdown since its inception was -98.89%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for EBS and NVO.
Loading charts...
Drawdown Indicators
| EBS | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.89% | -74.70% | -24.19% |
Max Drawdown (1Y)Largest decline over 1 year | -44.24% | -49.17% | +4.93% |
Max Drawdown (3Y)Largest decline over 3 years | -83.91% | -74.70% | -9.21% |
Max Drawdown (5Y)Largest decline over 5 years | -97.73% | -74.70% | -23.03% |
Max Drawdown (10Y)Largest decline over 10 years | -98.89% | -74.70% | -24.19% |
Current DrawdownCurrent decline from peak | -94.18% | -66.66% | -27.52% |
Average DrawdownAverage peak-to-trough decline | -41.23% | -17.81% | -23.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.81% | 32.54% | -7.73% |
Volatility
EBS vs. NVO - Volatility Comparison
Emergent BioSolutions Inc. (EBS) has a higher volatility of 17.79% compared to Novo Nordisk A/S (NVO) at 11.74%. This indicates that EBS's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| EBS | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.79% | 11.74% | +6.05% |
Volatility (6M)Calculated over the trailing 6-month period | 48.07% | 38.27% | +9.80% |
Volatility (1Y)Calculated over the trailing 1-year period | 82.47% | 52.05% | +30.42% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 102.28% | 38.45% | +63.83% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 79.78% | 32.60% | +47.18% |
Dividends
EBS vs. NVO - Dividend Comparison
EBS has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.93%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EBS Emergent BioSolutions Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.65% | 0.00% |
NVO Novo Nordisk A/S | 3.93% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
EBS vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Emergent BioSolutions Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
EBS vs. NVO - Profitability Comparison
EBS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Emergent BioSolutions Inc. reported a gross profit of 61.20M and revenue of 156.10M. Therefore, the gross margin over that period was 39.2%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
EBS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Emergent BioSolutions Inc. reported an operating income of 0.00 and revenue of 156.10M, resulting in an operating margin of 0.0%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
EBS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Emergent BioSolutions Inc. reported a net income of 0.00 and revenue of 156.10M, resulting in a net margin of 0.0%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
EBS and NVO have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
EBS has higher volatility (17.79%) compared to NVO (11.74%). In terms of maximum drawdown, EBS dropped -98.89% vs NVO's -74.70%.
EBS currently has the higher Sharpe Ratio (0.32 vs -0.67), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for EBS and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer